Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Accumulated Expenses (2023 - 2025)

Immunome's Accumulated Expenses history spans 3 years, with the latest figure at $11.5 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 96.67% year-over-year to $11.5 million; the TTM value through Dec 2025 reached $11.5 million, up 96.67%, while the annual FY2025 figure was $11.5 million, 96.67% up from the prior year.
  • Accumulated Expenses reached $11.5 million in Q4 2025 per IMNM's latest filing, up from $7.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $20.3 million in Q2 2024 to a low of $827000.0 in Q1 2023.
  • Average Accumulated Expenses over 3 years is $7.1 million, with a median of $5.8 million recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: surged 1211.25% in 2024, then crashed 72.4% in 2025.
  • A 3-year view of Accumulated Expenses shows it stood at $8.0 million in 2023, then decreased by 26.97% to $5.9 million in 2024, then skyrocketed by 96.67% to $11.5 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Accumulated Expenses are $11.5 million (Q4 2025), $7.2 million (Q3 2025), and $5.6 million (Q2 2025).